Skip to main content

Table 2 Crude and adjusted odds ratios (ORs) associated with treatment for individual cardiometabolic risk factors

From: A Bayesian multivariate latent t-regression model for assessing the association between corticosteroid and cranial radiation exposures and cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia: a PETALE study

ORa (95% credible interval)b

 

Crude

Adjusted

(including WBC count)

Adjusted

(without WBC count)

Obesity

 LD/CRT

1.64/1.56

(0.84, 2.93)

1.64/1.53

(0.77, 3.07)

1.79/1.69

(0.88, 3.32)

 HD/CRT

1.29/1.21

(0.60, 2.40)

1.03/0.94

(0.40, 2.19)

1.19/1.10

(0.51, 2.37)

Insulin resistance

 LD/CRT

1.43/1.32

(0.61, 2.94)

1.28/1.16

(0.47, 2.84)

1.69/1.55

(0.68, 3.55)

 HD/CRT

1.97/1.82

(0.81, 4.02)

1.22/1.08

(0.41, 2.78)

1.85/1.67

(0.69, 4.01)

(Pre-)hypertension

 LD/CRT

2.02/1.82

(0.75, 4.49)

1.90/1.67

(0.63, 4.51)

1.77/1.56

(0.61, 4.16)

 HD/CRT

2.00/1.79

(0.69, 4.54)

2.25/1.84

(0.56, 6.22)

2.00/1.70

(0.54, 5.25)

Dyslipidemia

 LD/CRT

1.94/1.86

(1.02, 3.33)

2.11/1.98

(1.02, 3.88)

1.82/1.72

(0.91, 3.31)

 HD/CRT

2.36/2.23

(1.16, 4.26)

1.95/1.80

(0.81, 3.99)

1.55/1.44

(0.69, 3.04)

  1. Point estimates are posterior means/medians based on 10,000 draws. LD low-dose corticosteroids, HD high-dose corticosteroids, CRT cranial radiotherapy, WBC white blood cell. a: The baseline treatment level is LD/No CRT. b: Endpoints are 2.5 and 97.5 empirical percentiles
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us